Malaria vaccine underway
2004/10/18 Rementeria Argote, Nagore - Elhuyar Zientziaren Komunikazioa
![](images/E041018.jpg)
This vaccine does not prevent infection, but can prevent the development of the disease. They have tested it with 2,022 boys and girls aged one to four, which means a 30% reduction in the risk of developing malaria. In addition, the vaccine is more effective in the more severe variants of the disease, which reduces the risk by 58%, and with children around a year of age, 71% less risk.
Vaccine developed in Belgium by GlaxoSmith Kline Biological. It is a combination of techniques that help the immune system fight the malaria parasite. Among other things, it contains a part of a superficial parasite protein, which binds to a part of the hepatitis B virus protein, which increases the immune system response.
Photo: WHO.
![](https://elia.eus/static/elhuyar/img/elia_RGB.png)
Gai honi buruzko eduki gehiago
Elhuyarrek garatutako teknologia